undamentalytics Newsletter
Sign in

Immunome Inc. key statistics and ratios

In fiscal 2025, Immunome Inc. had return on equity of -52.1% and a net margin of -3060.0%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Net margin−761.9%<−999%<−999%—
Return on equity−89.1%−194.6%−52.1%−43.9%
Return on assets−71.9%−150.7%−46.0%−40.7%
R&D as % of revenue164.7%>999%>999%—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $565m
Short-term assets $538mLonger-term assets $27m
What it owes, and who funded it · $565m
Short-term liabilities $36mLonger-term liabilities $5mShareholders' equity $525m
  • Short-term assets cover short-term liabilities $538m of assets due within a year against $36m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $538m short-term assets against $5m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Immunome Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Immunome Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immunome Inc.